During the last session, Capricor Therapeutics Inc (NASDAQ:CAPR)’s traded shares were 1.25 million, with the beta value of the company hitting 4.09. At the end of the trading day, the stock’s price was $14.96, reflecting an intraday gain of 8.41% or $1.16. The 52-week high for the CAPR share is $23.40, that puts it down -56.42 from that peak though still a striking 76.47% gain since the share price plummeted to a 52-week low of $3.52. The company’s market capitalization is $680.22M, and the average intraday trading volume over the past 10 days was 1.39 million shares, and the average trade volume was 2.17 million shares over the past three months.
Capricor Therapeutics Inc (CAPR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CAPR has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it.
Capricor Therapeutics Inc (NASDAQ:CAPR) trade information
Capricor Therapeutics Inc (CAPR) registered a 8.41% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 8.41% in intraday trading to $14.96, hitting a weekly high. The stock’s 5-day price performance is 6.78%, and it has moved by -23.83% in 30 days. Based on these gigs, the overall price performance for the year is 192.19%. The short interest in Capricor Therapeutics Inc (NASDAQ:CAPR) is 5.59 million shares and it means that shorts have 3.54 day(s) to cover.
The consensus price target of analysts on Wall Street is $15, which implies an increase of 0.27% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $10 and $21.5 respectively. As a result, CAPR is trading at a discount of -43.72% off the target high and 33.16% off the low.
Capricor Therapeutics Inc (CAPR) estimates and forecasts
Statistics show that Capricor Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Capricor Therapeutics Inc (CAPR) shares have gone up 209.73% during the last six months, with a year-to-date growth rate less than the industry average at -46.99% against 12.30.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 30.59%. While earnings are projected to return -43.37% in 2025.
CAPR Dividends
Capricor Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Capricor Therapeutics Inc (NASDAQ:CAPR)’s Major holders
Capricor Therapeutics Inc insiders own 16.75% of total outstanding shares while institutional holders control 18.55%, with the float percentage being 22.28%. BLACKROCK INC. is the largest shareholder of the company, while 106.0 institutions own stock in it. As of 2024-06-30, the company held over 1.63 million shares (or 5.194% of all shares), a total value of $7.77 million in shares.
The next largest institutional holding, with 1.55 million shares, is of VANGUARD GROUP INC’s that is approximately 4.9401% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $7.39 million.
